Literature DB >> 17385003

Enhanced TGF-beta/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor.

Yuko Okazaki1, Yasushi Yamasaki, Haruhito A Uchida, Kazunori Okamoto, Minoru Satoh, Keisuke Maruyama, Yohei Maeshima, Hitoshi Sugiyama, Takeshi Sugaya, Naoki Kashihara, Hirofumi Makino.   

Abstract

BACKGROUND: Angiotensin II (AII) and transforming growth factor-beta (TGF-beta) are closely involved in the pathogenesis of diabetic nephropathy (DN). AII is known to induce TGF-beta production in resident renal cells, including glomerular mesangial cells and tubular epithelial cells. TGF-beta receptor types I and II (TGF-betaRI, II) are up-regulated in the diabetic kidney. The aim of this study was to clarify the role of AII in the regulation of the TGF-beta system in the early stage of DN using AII type1a receptor-deficient(AT1a(-/-)) mice.
METHODS: We investigated the expression of TGF-beta1, TGF-betaRI, II, and Smad signaling in AT1a(-/-) mice with streptozotocin (STZ)-induced DN. Mice were killed 10 and 20 days after the induction of hyperglycemia. The expression of TGF-beta receptors was analyzed by immunohistochemical staining and reverse transcriptase-polymerase chain reaction (RT-PCR). TGF-beta-specific Smad signaling was analyzed by electrophoretic mobility shift assay and Western blotting.
RESULTS: The expression of both TGF-betaRI and RII was up-regulated in the glomerular tufts and vasculature in diabetic AT1a(+/+) mice kidney by immunohistochemistry. RT-PCR revealed that mRNAs for TGF-betaRI and RII were also up-regulated. Smad2 and 4 protein levels were reduced in the renal cortex after the induction of diabetes, with an increase of Smad 3/4 complex in the nucleus. The expression of TGF-beta receptors increased in both diabetic AT1a(-/-) and AT1a(+/+) mice. Smad signaling in AT1a(-/-) mice was also enhanced.
CONCLUSIONS: Our results suggest that the complete blockade of the AT1a-mediated pathway has a minimal effect on the enhanced TGF-beta/Smad signaling in the early stage of DN, at least in the AT1a(-/-) model.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17385003     DOI: 10.1007/s10157-006-0456-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  41 in total

Review 1.  Role of angiotensin II in diabetic nephropathy.

Authors:  D J Leehey; A K Singh; N Alavi; R Singh
Journal:  Kidney Int Suppl       Date:  2000-09       Impact factor: 10.545

Review 2.  Transforming growth factor beta in diabetic nephropathy.

Authors:  W A Border; T Yamamoto; N A Noble
Journal:  Diabetes Metab Rev       Date:  1996-12

Review 3.  Involvement of transforming growth factor-beta and its receptors in the pathogenesis of diabetic nephrology.

Authors:  F N Ziyadeh; D C Han
Journal:  Kidney Int Suppl       Date:  1997-09       Impact factor: 10.545

Review 4.  Role of anti-TGF-beta antibodies in the treatment of renal injury.

Authors:  Elena Gagliardini; Ariela Benigni
Journal:  Cytokine Growth Factor Rev       Date:  2005-10-28       Impact factor: 7.638

5.  Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism.

Authors:  Juan Rodríguez-Vita; Elsa Sánchez-López; Vanesa Esteban; Mónica Rupérez; Jesús Egido; Marta Ruiz-Ortega
Journal:  Circulation       Date:  2005-05-09       Impact factor: 29.690

6.  Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation.

Authors:  M Stopa; D Anhuf; L Terstegen; P Gatsios; A M Gressner; S Dooley
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

7.  G1 kinases and transforming growth factor-beta signaling are associated with a growth pattern switch in diabetes-induced renal growth.

Authors:  H C Huang; P A Preisig
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

Review 8.  The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms.

Authors:  G Wolf; F N Ziyadeh
Journal:  Am J Kidney Dis       Date:  1997-01       Impact factor: 8.860

9.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.

Authors:  T Yamamoto; T Nakamura; N A Noble; E Ruoslahti; W A Border
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus.

Authors:  A A Like; A A Rossini
Journal:  Science       Date:  1976-07-30       Impact factor: 47.728

View more
  5 in total

1.  Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy.

Authors:  T Zhou; X He; R Cheng; B Zhang; R R Zhang; Y Chen; Y Takahashi; A R Murray; K Lee; G Gao; J-X Ma
Journal:  Diabetologia       Date:  2011-10-21       Impact factor: 10.122

2.  Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy.

Authors:  Harmeet Kaur; Alexander Chien; Ishwarlal Jialal
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-08

3.  Effects of Panax notoginoside on the expression of TGF-β1 and Smad-7 in renal tissues of diabetic rats.

Authors:  Qingnian Tu; Juan Qin; Hui Dong; Fuer Lu; Wei Guan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-04-20

4.  Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.

Authors:  Urmi Sengupta; Sanchaita Ukil; Nevenka Dimitrova; Shipra Agrawal
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

5.  Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis.

Authors:  Vivek P Singh; Bao Le; Renu Khode; Kenneth M Baker; Rajesh Kumar
Journal:  Diabetes       Date:  2008-10-01       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.